RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.
Gong S, Chen Y, Meng F, Zhang Y, Wu H, Li C, Zhang G.
Gong S, et al.
FASEB J. 2019 Apr;33(4):5350-5365. doi: 10.1096/fj.201801529RR. Epub 2019 Feb 15.
FASEB J. 2019.
PMID: 30768358
Taken together, RCC2 may function as an oncogene, regulating the RalA signaling pathway, and intervention of RCC2 expression might be a promising therapeutic strategy for DDP-resistant ovarian cancer.-Gong, S., Chen, Y., Meng, F., Zhang, Y., Wu, H., Li, C., Zhang, G …
Taken together, RCC2 may function as an oncogene, regulating the RalA signaling pathway, and intervention of RCC2 expression might be a prom …